AU2013266215B2 - Non-natural consensus albumin binding domains - Google Patents

Non-natural consensus albumin binding domains Download PDF

Info

Publication number
AU2013266215B2
AU2013266215B2 AU2013266215A AU2013266215A AU2013266215B2 AU 2013266215 B2 AU2013266215 B2 AU 2013266215B2 AU 2013266215 A AU2013266215 A AU 2013266215A AU 2013266215 A AU2013266215 A AU 2013266215A AU 2013266215 B2 AU2013266215 B2 AU 2013266215B2
Authority
AU
Australia
Prior art keywords
albumin binding
binding domain
seq
isolated
abdcon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013266215A
Other languages
English (en)
Other versions
AU2013266215A1 (en
Inventor
Steven Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AU2013266215A1 publication Critical patent/AU2013266215A1/en
Priority to AU2017261625A priority Critical patent/AU2017261625B2/en
Application granted granted Critical
Publication of AU2013266215B2 publication Critical patent/AU2013266215B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2013266215A 2012-05-25 2013-05-23 Non-natural consensus albumin binding domains Active AU2013266215B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017261625A AU2017261625B2 (en) 2012-05-25 2017-11-17 Non-natural consensus albumin binding domains

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261651642P 2012-05-25 2012-05-25
US61/651,642 2012-05-25
US201361776918P 2013-03-12 2013-03-12
US61/776,918 2013-03-12
PCT/US2013/042429 WO2013177398A2 (en) 2012-05-25 2013-05-23 Non-natural consensus albumin binding domains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017261625A Division AU2017261625B2 (en) 2012-05-25 2017-11-17 Non-natural consensus albumin binding domains

Publications (2)

Publication Number Publication Date
AU2013266215A1 AU2013266215A1 (en) 2014-12-04
AU2013266215B2 true AU2013266215B2 (en) 2017-12-07

Family

ID=49622071

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013266215A Active AU2013266215B2 (en) 2012-05-25 2013-05-23 Non-natural consensus albumin binding domains
AU2017261625A Active AU2017261625B2 (en) 2012-05-25 2017-11-17 Non-natural consensus albumin binding domains

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017261625A Active AU2017261625B2 (en) 2012-05-25 2017-11-17 Non-natural consensus albumin binding domains

Country Status (15)

Country Link
US (3) US9156887B2 (enExample)
EP (1) EP2855509B1 (enExample)
JP (3) JP2015519345A (enExample)
KR (1) KR102053674B1 (enExample)
CN (1) CN104470944B (enExample)
AU (2) AU2013266215B2 (enExample)
BR (1) BR112014029409B1 (enExample)
CA (1) CA2874646C (enExample)
DK (1) DK2855509T3 (enExample)
EA (1) EA036487B1 (enExample)
ES (1) ES2670442T3 (enExample)
IL (2) IL235808A (enExample)
MX (1) MX355041B (enExample)
PT (1) PT2855509T (enExample)
WO (1) WO2013177398A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
CA2902789A1 (en) * 2013-03-14 2014-09-18 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
EP3288965B1 (en) * 2015-04-29 2019-06-26 Mediolanum Farmaceutici S.p.A. A soluble chimeric interleukin-10 receptor and therapeutic use thereof
WO2016204884A1 (en) * 2015-06-18 2016-12-22 Albert Einstein College Of Medicine, Inc. Fgf receptor ligands for treating diabetes and obesity
EP3374504B1 (en) * 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
CN106699842B (zh) * 2015-11-17 2020-06-12 上海交通大学 一种新的抗炎小分子多肽及其应用
WO2017151707A1 (en) 2016-03-01 2017-09-08 The Board Of Trustees Of The University Of Illinois L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability
KR102568559B1 (ko) 2016-12-14 2023-08-18 얀센 바이오테크 인코포레이티드 Cd8a-결합 섬유결합소 iii형 도메인
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
JP7332157B2 (ja) 2017-01-24 2023-08-23 ノースウェスタン ユニバーシティ アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体
US11578315B2 (en) 2017-08-11 2023-02-14 The Board Of Trustees Of The University Of Illinois Truncated guinea pig L-asparaginase variants and methods of use
EP3765496A1 (en) 2018-03-13 2021-01-20 Affibody AB Polypeptides based on a novel scaffold
KR102282240B1 (ko) 2018-12-06 2021-07-28 경상국립대학교산학협력단 지속형 엑센딘-4 및 이의 용도
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
CN114786682B (zh) 2019-10-14 2024-07-16 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
CN115916818A (zh) 2019-12-11 2023-04-04 库利南肿瘤股份有限公司 抗cd19抗体和多特异性结合蛋白
US12351619B2 (en) 2019-12-18 2025-07-08 Aro Biotherapeutics Company Serum albumin-binding fibronectin type III domains and uses thereof
WO2021174107A2 (en) 2020-02-26 2021-09-02 Northwestern University Soluble ace2 variants and uses therefor
WO2021194183A1 (ko) * 2020-03-25 2021-09-30 ㈜큐리진 면역 회피성 항종양 아데노바이러스
CN114621354A (zh) * 2020-12-11 2022-06-14 正大天晴药业集团股份有限公司 Fab-白蛋白结合肽融合蛋白及其制备方法和应用
JP2024517610A (ja) 2021-04-14 2024-04-23 アロ・バイオセラピューティクス・カンパニー Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン
KR20240031947A (ko) 2021-04-14 2024-03-08 에이알오 바이오테라퓨틱스 컴패니 Fn3 도메인-시르나 접합체 및 이의 용도
CN113336860B (zh) * 2021-06-02 2022-07-01 北京大学 一种具有靶向和长效功能的重组水蛭素融合蛋白及其编码基因和应用
KR20250087648A (ko) * 2022-11-09 2025-06-16 리플리겐 코포레이션 친화도 제제
EP4634216A1 (en) 2022-12-16 2025-10-22 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes
EP4788689A1 (en) 2023-10-03 2026-08-12 BicycleTx Limited Bicyclic peptide ligand complexes specific for tfr1
AU2024401183A1 (en) * 2023-12-12 2026-04-30 Navigo Proteins Gmbh Novel serum albumin-binding fusion proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141329A1 (en) * 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
JPH07507682A (ja) * 1992-05-07 1995-08-31 アクティノバ・リミテッド Ｌプロテインに由来する免疫グロブリン結合性タンパク質およびその用途
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
ES2243007T3 (es) 1997-09-16 2005-11-16 Egea Biosciences Llc Sintesis quimica completa y sintesis de genes de genomas.
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
DE08786222T1 (de) 2007-07-31 2010-11-25 Affibody Ab Neue albuminbindende zusammensetzungen, verfahren und anwendungen
CA2729567C (en) 2008-06-30 2018-04-24 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
MX2011004550A (es) * 2008-10-31 2011-07-20 Centocor Ortho Biotech Inc Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos.
JP5557254B2 (ja) * 2009-02-10 2014-07-23 国立大学法人 琉球大学 薬物運搬体並びにこれを利用したアジュバントおよびワクチン
CN102596992B (zh) 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
JP6002659B2 (ja) 2010-04-13 2016-10-05 セルデックス・セラピューティクス・インコーポレイテッド ヒトｃｄ２７に結合する抗体およびその使用
HUE029622T2 (en) * 2010-04-30 2017-03-28 Janssen Biotech Inc Stabilized fibronectin domain compositions, methods and uses
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141329A1 (en) * 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JONSSON, A. et al., Protein Engineering, Design & Selection, 2008, vol. 21, no. 8, pages 515-527 *

Also Published As

Publication number Publication date
IL235808A0 (en) 2015-01-29
EA036487B1 (ru) 2020-11-16
DK2855509T3 (en) 2018-07-23
US20130316952A1 (en) 2013-11-28
JP7166081B2 (ja) 2022-11-07
WO2013177398A3 (en) 2014-03-27
US20160083436A1 (en) 2016-03-24
IL254652A0 (en) 2017-11-30
WO2013177398A2 (en) 2013-11-28
HK1209134A1 (en) 2016-03-24
BR112014029409B1 (pt) 2022-11-29
KR20150016585A (ko) 2015-02-12
CA2874646C (en) 2020-12-01
CA2874646A1 (en) 2013-11-28
IL254652B (en) 2019-12-31
PT2855509T (pt) 2018-08-03
EP2855509A4 (en) 2016-01-13
AU2017261625A1 (en) 2017-12-07
ES2670442T3 (es) 2018-05-30
MX2014014384A (es) 2015-05-11
CN104470944B (zh) 2021-09-14
EP2855509A2 (en) 2015-04-08
US10280200B2 (en) 2019-05-07
EA201590136A1 (ru) 2016-02-29
CN104470944A (zh) 2015-03-25
KR102053674B1 (ko) 2019-12-09
JP2018171063A (ja) 2018-11-08
AU2013266215A1 (en) 2014-12-04
US9156887B2 (en) 2015-10-13
MX355041B (es) 2018-03-28
BR112014029409A2 (enExample) 2017-08-15
JP2021019595A (ja) 2021-02-18
JP2015519345A (ja) 2015-07-09
IL235808A (en) 2017-10-31
US20180009854A1 (en) 2018-01-11
AU2017261625B2 (en) 2019-11-21
EP2855509B1 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
US10280200B2 (en) Non-natural consensus albumin binding domains
EP2536757B1 (en) Fibronectin based scaffold domain proteins that bind il-23
US9260496B2 (en) Fibronectin based scaffold domain proteins that bind IL-23
KR102461666B1 (ko) 혈청 알부민 결합 피브로넥틴 iii 형 도메인
CA3161326A1 (en) Designed ankyrin repeat domains with altered surface residues
CN105477641A (zh) 生物合成的脯氨酸/丙氨酸无规卷曲多肽及其用途
AU2016242905A1 (en) Protoxin-II variants and methods of use
EP3052519A1 (en) Protoxin-ii variants and methods of use
Baumann et al. Identification of a potential modification site in human stromal cell‐derived factor‐1
HK1209134B (en) Non-natural consensus albumin binding domains
KR20240035847A (ko) 인간 파이브로넥틴 유형 iii 단백질 스캐폴드
EA045108B1 (ru) Выделенный искусственный альбумин-связывающий домен и содержащий его слитый белок
WO2021195177A1 (en) Qty fc fusion water soluble receptor proteins
HK1179276B (en) Fibronectin based scaffold domain proteins that bind il-23

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)